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Abstract
Background: The new JAK3 inhibitor, CP690,550, has shown efficacy in the treatment of rheumatoid arthritis. The
present study was undertaken to assess the effects of CP690,550 on cytokine production and cellular signaling in
human CD4
+ T cells.
Results: CD4
+ T cells produced IL-2, IL-4, IL-17, IL-22 and IFN-g in following stimulation with a CD3 antibody. At
the optimal concentration, CP690,550 almost completely inhibited the production of IL-4, IL-17, IL-22 and IFN-g
from these activated CD4
+ T cells, but only had marginal effects on IL-2 production. Moreover CP690,550 inhibited
anti-CD3-induced phosphorylation of STAT1, STAT3, STAT4, STAT5, and STAT6, but not the TCR-associated
phosphorylation of ZAP-70.
Conclusions: Therefore, CP690,550-mediated modification of the JAK/STAT pathway may be a new
immunosuppressive strategy in the treatment of autoimmune diseases.
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Background
Janus kinases (JAKs) are cytoplasmic tyrosine kinases that
participate in the signaling of cell surface receptors, parti-
cularly cytokine receptors [1]. Ligand-cytokine receptor
binding induces activation of JAKs, which initiate signal-
ing by phosphorylating cytokine receptors and creating
docking sites for signaling proteins, known as signal
transducers and activators of transcription (STATs) [2].
JAKs catalyze STAT phosphorylation to facilitate STAT
dimerization, transport to the nucleus and ultimately reg-
ulate gene expression [3]. Of the members of the JAK
family, JAK3 has features that make it a potentially
attractive target for immunosuppression, since JAK3
associates with the common gamma (cg) chain, which is
shared by receptors of IL-2, IL-4, IL-7, IL-9, IL-15 and
IL-21 [4]. Moreover, mice and humans with a heritable
absence or mutation of JAK3 express a severe combined
immunodeficiency phenotype [5,6]. Therefore selective
inhibition of JAK3 represents an optimal strategy for
immunosuppression and the treatment of autoimmune
diseases [7]. CP690,550, a JAK3 inhibitor that is currently
in clinical trials, has been shown to significantly reduce
joint inflammation in rheumatoid arthritis (RA) [8,9].
The JAK/STAT pathways influence cell-fate decisions
made by differentiating naïve T cells, helping to control
their development into Th1 Th2 and Th17 cells [10].
Commitment to the Th1 lineage requires STAT1- and
STAT4-dependent mechanisms that induce IFN-g and
T-bet expression [11]. On the other hand, differentiation
towards the Th2 developmental pathway requires STAT6
[12]. STAT3 has emerged as an important determinant
of T cell differentiation towards the inflammatory Th17
T cell lineage [13]. As the JAK/STAT pathway plays a
pivotal role in T cell differentiation and cytokine signal-
ing in T cells, we postulated that selective inhibition of
JAKs with CP690,550 would modulate T cell functions
and characteristics. In this study, we assessed the effects
of a pharmacological inhibitor of JAK3, CP690,550, on
gene expression and secretion of cytokines by human
CD4
+ T cells. We also examined whether CP690,550
affected the STAT activation status in activated CD4
+
T cells.
* Correspondence: migita@nmc.hosp.go.jp
1Department of Rheumatology and Clinical Research Center, NHO Nagasaki
Medical Center, Kubara 2-1001-1, Omura 856-8652, Japan
Full list of author information is available at the end of the article
Migita et al. BMC Immunology 2011, 12:51
http://www.biomedcentral.com/1471-2172/12/51
© 2011 Migita et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Results
Cytokine production by CD4 T cells is greatly reduced by
CP690,550
To investigate the potential role of JAKs in T cell activa-
tion, CD4
+ T cells isolated from healthy subjects were sti-
mulated with a CD3 monoclonal antibody in the
presence of CP690,550 for 2 days. As shown in Figure 1,
freshly isolated CD4
+ T cells secreted a significant
amount of IL-4 (A), IFN-g (B), IL-17A (C) and IL-22 (D)
in response to stimulation with the CD3 antibody.
CP690,550 completely abrogated secretion of these cyto-
kines from CD4
+ T cells. Meanwhile, CP690,550 did not
affect the secretion of IL-2 by anti-CD3-stimulated CD4
+
T cells (Figure 1E).
To confirm these findings, we examined mRNA levels
of these cytokines in CD4
+ T cells using real-time PCR.
Stimulation for 8 hrs with the CD3 antibody induced
IL-2 (Figure 2A) and IFN-g mRNA (Figure 2B) expres-
sion in CD4
+ T cells. The increased IFN-g mRNA levels
were down regulated by CP690,550 (Figure 2B), whereas
Figure 1 Effects of CP690, 550 activated CD4
+ T cell cytokine production. CD4
+ T cells were stimulated with CD3 monoclonal antibodies in
the presence or absence of CP690,550 for 48 hr. Supernatants were collected and the levels of IL-2, IL-4 (A), IFN-g (B), IL-17A (C), IL-22 (D) and IL-
2 (E) were measured by ELISA. The figure shows the means ± SD of the three independent experiments performed in triplicate. * p < 0.001 vs
CD3 Ab-stimulated lymphocytes.
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Page 2 of 10Figure 2 Effects of CP690, 550 on cytokine genes expression in activated CD4
+ Tc e l l s .C D 4
+ T cells were stimulated with CD3
monoclonal antibodies in the presence or absence of CP690,550. After 8-hr or 24-hr stimulation, total RNA was extracted and IL-2 (A), IFN-g (B),
IL-4 (C) and IL-17A (D) mRNA expression was measured by real-time PCR. * p < 0.001 vs CD3 Ab-stimulated lymphocytes. The results show a
representative result from three independent experiments.
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Page 3 of 10the anti-CD3-stimulated expression of IL-2 mRNA was
not affected (Figure 2A). The expression of IL-4 and IL-
17 mRNA was marginally induced after 8 hrs of anti-
CD3 stimulation. In contrast, when CD4
+ T cells were
stimulated with the CD3 antibody for 24 hrs, expression
of IL-4 and IL-17 mRNA was greatly induced (Figure
2C, D). Consistent with the protein data, the induction
of IL-4 and IL-17 mRNA in anti-CD3-stimulated CD4
+
T cells was down regulated by CP690,550 (Figure 2C,
D). We next examined the effects of CP690,550 on con-
canavalin A (Con A)-activated CD4
+ T cells. As shown
in Figure 3, CP690,550 inhibited cytokine mRNA
expression of Con A-activated CD4
+ Tc e l l s .F u r t h e r -
more, CP690,550 inhibited granzyme B mRNA expres-
sions in anti-CD3-stimulated CD8
+ T cells (Figure 4).
Effects of CP690,550 on CD4
+ T cell proliferation
Next, we examined the effects of CP690,550 on T cell
proliferation. As shown in Figure 5, CP690,550 pre-treat-
ment significantly inhibited anti-CD3-induced CD4
+ T
cell proliferation. We also investigated whether
CP690,550 pre-treatment induces apoptosis in anti-CD3-
activated CD4
+ T cells. CP690,550 pre-treatment did not
result in an increase in the percentages of annexin V-
positive/PI-negative early apoptotic cells (Figure 6).
CP690,550 abrogated CD3-induced phosphorylation of
STATs in CD4
+ T cells
The STAT transcription factors help mediate the differ-
entiation of CD4
+ T cells into each of the T helper (Th)
subsets and are involved in lineage-specific expression
of cytokines. To determine whether CP690,550 affected
the phosphorylation of the STATs in the T cell activa-
tion process, we assessed the phosphorylation-status of
STATs in anti-CD3-stimulated T cells (Figure 7). After
24 hr of anti-CD3 stimulation, phosphorylation of
STAT1, STAT4, STAT5 and STAT6 was induced in
CD4
+ T cells. These phosphorylation events were inhib-
ited by 100 nM CP690,550 at 24 and also at 48 hrs.
CD3 antibody stimulation did not augment the phos-
phorylation of STAT3 after 24 hrs, but this was evident
after 48 hrs. Similarly, CP690,550 also inhibited the late
phase STAT3 phosphorylation in activated CD4
+
T cells.
CP690,550 did not affect CD3-induced phosphorylation of
ZAP-70 in CD4
+ T cells
Finally, we tested the effect of CP690,550 on TCR-direc-
ted signaling by assessing TCR-associated phosphoryla-
tion of ZAP-70. ZAP-70 phosphorylation was induced
in CD4
+ T cells after stimulation for 30 min with a
CD3-antibody, but CP690,550 exhibited no inhibitory
effect on ZAP-70 phosphorylation (Figure 8).
Discussion
It is well-established that cytokines play a critical role in
regulating autoimmunity and inflammation, since target-
ing cytokines has been shown to be effective in the
treatment of RA [14]. However, targeting intracellular
cytokine signaling using protein kinase inhibitors,
appears to be a new strategy for immunosuppression
[15]. CP690,550, a JAK inhibitor that is currently in clin-
ical trials, has shown significant efficacy in the treatment
of RA [8,9]. However, the precise mechanisms responsi-
ble for CP690,550-mediated immunosuppression have
not been elucidated.
Naïve CD4
+ T cells can differentiate into two major
distinct phenotypes, Th1 and Th2 cells, which are char-
acterized by polarized cytokine expression patterns [16].
TCR signaling plays an important role in this differentia-
tion by inducing Th-specific cytokines [17]. Naïve CD4
+
T cells are capable of producing IFN-g and IL-4 when
they are stimulated with peptide/MHC class II complexes
on antigen-presenting cells (APC) [18]. The endogenous
production of IFN-g has been shown to be sufficient for
Th1 differentiation, whereas IL-4 is critical for Th2 dif-
ferentiation [19]. In this study, we examined the effects of
CP690,550 on the production of these cytokines from
CD4
+ T cells activated by CD3-stimulation. Our data
indicated that CP690,550, a JAK3 inhibitor, abrogated
IFN-g and IL-4 production from CD4
+ T cells trigged a
CD3 antibody.
JAKs are cytoplasmic tyrosine kinases that participate
in the signaling of the cytoplasmic receptor of the cg
chain family receptors for IL-2, IL-4, IL-7, IL-9, IL-15
and IL-21 [20]. Ligand receptor-induced activation of
JAKs initiates signaling by phosphorylation of the cyto-
kine receptors and catalyzes STAT phosphorylation,
facilitating STAT dimerization, transport to the nucleus
and gene regulation [3]. Therefore, it is possible that
CP690,550 affects the STAT activation processes. Th1
differentiation depends on signaling through the IFN-g
receptor, the IL-12 receptor and their downstream tran-
scription factors, STAT1 and STAT4 [21]. Similarly,
mature Th2 differentiation depends on the IL-4 receptor
and its downstream transcription factor STAT6 [12]. We
demonstrated that CP690,550 inhibited STAT1, STAT4
and STAT6 activation, in addition to IFN-g and IL-4 pro-
duction, in TCR-stimulated CD4
+ T cells. These findings
suggest that CP690,550 inhibits the production of Th1-
or Th2-specific cytokines, as well as cytokine receptor
signaling.
The JAK1-STAT1 and JAK2-STAT4 signaling path-
ways are known to be important for Th1 cell differentia-
tion, but JAK3 has not previously been implicated in
Th1 cell differentiation [22]. In contrast, JAK3 is essen-
tial for Th2 differentiation, since it plays an essential
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CP690,550, a JAK3 inhibitor, affected the CD3-induced
Th1-related activation of JAK1-STAT1 or JAK2-STAT4
in addition to the Th2-related activation of JAK3-
STAT6. CP690,550 was originally believed to be a JAK3
inhibitor [24], but it has now become clear that this
compound also inhibits JAK1 and JAK2 with similar
IC50-values [25,26]. Therefore, it is possible that
Figure 3 Effects of CP690, 550 on cytokine genes expression in Con-A activated CD4
+ Tc e l l s .C D 4
+ T cells were stimulated with
concanavalin A in the presence or absence of CP690,550. After 24-hr stimulation, total RNA was extracted and IL-2, IFN-g, IL-4, IL-17A and IL-22
mRNA expression was measured by real-time PCR. The results show a representative result from three independent experiments.
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cytokines, but also the induction of Th1-related cyto-
kines via JAK1 and JAK2, in addition to JAK3.
More recently, the IL-2-JAK3-STAT5 axis has been
demonstrated to regulate Th1 cell differentiation, sug-
gesting that IL-2-mediated JAK3-STAT5 signaling may
generically operate in the production of Th1-related
cytokines [27]. We also demonstrated that the CD3 anti-
body-induced phosphorylation of STAT5 was down
regulated by CP690,550, suggesting that JAK3 inhibition
by CP690,550 down regulated STAT5-dependent cyto-
kine signaling.
It is particularly interesting to evaluate the contribution
of Th17 cells to the pathogenesis of RA, as IL-17 is
involved in immune-mediated articular damage [28]. The
current view of human Th17 development is that IL-6 and
IL-23 are key cytokines that initiate differentiation and
maintenance of this lineage [29]. Th17 cells are also major
producers of IL-22, in addition to IL-17 [30]. In contrast
with mouse T cells, TCR stimulation alone has been
shown to be sufficient to induce both IL-17 in humans
T cells [31]. Indeed, anti-CD3-stimulation induced secre-
tion of both IL-17 and IL-22 from CD4
+ T cells in our
study. Our data also demonstrated that CP690,550 almost
completely inhibited CD3-induced production of IL-17 or
IL-22 from human CD4
+ T cells. Recent evidence has sup-
ported a new role for STAT3, in the differentiation of
Th17 cells [32]; STAT3-deficient mice fail to produce
IL-17 and restoration of STAT3 rescues the IL-17 defect
[33]. It has also been reported that activated STAT3 binds
directly to the STAT3-binding sites in the promoter of the
IL-17 gene, increasing its expression [34]. These findings
indicate that STAT3 signaling is important for IL-17
induction and Th17 differentiation. In this study, anti-
CD3 stimulation activated STAT3 during the late phase of
T cell activation (i.e., 48 hrs), which was blocked by
CP690,550. This impaired STAT3 activation may have
partially contributed to the suppression of Th17-related
cytokine production by CP690,550.
Resting T cells require the sequential activation of two
signaling pathways to differentiate. First, antigen stimu-
lation of the TCR/CD3 complex leads to the expression
of IL-2 and IL-2R. Second, the binding of IL-2 to its
Figure 4 Effects of CP690, 550 on granzyme B mRNA expression in activated CD8
+ Tc e l l s .C D 8
+ T cells were stimulated with CD3
monoclonal antibodies in the presence or absence of CP690,550. After 8-hr or 24-hr stimulation, total RNA was extracted and granzyme B mRNA
expression was measured by real-time PCR. The results show a representative result from two independent experiments.
Figure 5 Anti-proliferative effects of CP690,550 on CD3 Ab
activated CD4
+ T cells. CD4
+ T cells were stimulated with CD3
monoclonal antibodies in the presence or absence of CP690,550.
After 48-hr, proliferation was determined by the XTT assay. * p =
0.023 vs CD3 Ab-stimulated lymphocytes. ** p = 0.010 vs CD3 Ab-
stimulated lymphocytes. The results are expressed as the mean ±
SD of two independent experiments.
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our study, CP690,550 did not directly affect TCR-
mediated signaling, i.e., ZAP-70 activation. However,
CP690,550 abrogated the subsequent activation of the
STATs (STAT1, 3, 4, 5, 6). These findings suggest that
CP690,550 induces immunosuppression by affecting
cytokine receptor-associated JAK/STAT signaling, which
is downstream of the TCR-signaling pathway. These
findings may provide important information concerning
the mechanisms of CP690,550-mediated immunosup-
pression in the treatment of RA.
In T cell activation, the first signal is triggered by the
engagement of the TCR with the antigen after presenta-
tion by the antigen-presenting cell (APC), which is then
ultimately transmitted by the final signal triggered by cyto-
kine engagement of their receptors on T cells via the JAK/
STAT pathway [36]. In this study, we demonstrated that
CP690,550 abrogated the TCR-triggered production of
cytokines by affecting the JAK/STAT signaling pathway,
not the TCR-mediated signaling pathway. We believe that
small molecule inhibitors that target JAKs may provide
alternative therapeutic strategies for immunosuppression
in contrast to classical immunosuppressants, such as calci-
neurin inhibitors, that target TCR-mediated signaling.
Conclusion
CP690, 550 inhibited anti-CD3-induced IFN-g,I L - 4a n d
IL-17 production from CD4
+ T cells without affecting
Figure 6 Effects of CP690,550 on the apoptosis induction in CD3 Ab activated CD4
+ T cells.C D 4
+ T cells were stimulated with CD3
monoclonal antibodies in the presence or absence of CP690,550. After 24-hr, the cells were stained with FITC-conjugated Annexin V and PI and
were then analyzed by flow cytometry. Ten thousand cells were measured and plotted. The proportion of cells residing in each quadrant is
expressed as a percentage. Results are representative of 3 independent results.
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induced STAT1, STAT3, STAT4, STAT5 and STAT6
activation in CD4
+ T cells. Modification of the JAK/
STAT pathway using small molecule inhibitors may pro-
vide a new strategy for immunosuppression.
Methods
Reagents
JAK inhibitor, CP690,550 was obtained from Axon Bio-
chemicals (Postbus, Netherlands). Human CD3 mono-
clonal antibody (UCTH1) was purchased from BD
Biosciences (Franklin Lakes, NJ, USA). Phospho-specific
and pan antibodies against STAT-1 (Tyr701), STAT-3
(Tyr705), STAT-4 (Tyr639), STAT-5 (Tyr694), STAT-6
(Tyr641) and phospho-specific ZAP-70 (Tyr493) were
purchased from Cell Signaling Technology (Beverly, MA
USA).
Isolation of CD4
+ and CD8
+ T lymphocytes
Peripheral blood mononuclear cells were isolated from
peripheral blood of healthy volunteers by Ficoll-Hypaque
isopycnic centrifugation. Informed consent was obtained
from each of the individuals. Next, CD4
+ or CD8
+ T lym-
phocytes were positively selected by use of magnetic CD4
or CD8 MicroBeads (Miltenyi Biotec, Bergisch Gladbach,
Germany), as described by the manufacturer. More than
98% of the isolated cells were positive for CD3 and CD4,
as measured by flow cytometry. T cells were cultured in
Figure 7 CP690,550 inhibited STATs phosphorylation in CD3 Ab-activated CD4
+ T cells.C D 4
+ T cells were stimulated with CD3
monoclonal antibodies in the presence or absence of CP690, 550 for 24 hr and 48 hr. STAT1, STAT3, STAT4, STAT5 and STAT6 phosphorylations
were measured by western blotting. The results show a representative blot from three independent experiments.
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ciences; Falcon 3047) at 1.0 × 10
6 cells/ml in RPMI 1640
supplemented with 10% FBS at 37°C in a humidified incu-
bator with 5% CO2.
Cytokine enzyme-linked immunosorbent assay (ELISA)
The amounts of IFN-g,I L - 2 ,I L - 4 ,I L - 1 7 Aa n dI L - 2 2i n
the supernatants of the cultured CD4
+ T lymphocytes
was measured using commercial ELISA kits (R&D Sys-
tems, Minneapolis, MN) according to the manufacturer’s
instructions
Real-time polymerase chain reaction (PCR) analysis
Total cellular RNA was extracted with Trizol (Invitrogen,
Carlsbad, CA) according to the manufacturer’sp r o t o c o l .
First-strand cDNA was synthesized from 1 μg of total cel-
lular RNA using an RNA PCR kit (Takara Bio Inc., Otsu,
Japan) with random primers. Amplification of the IFN-g,
IL-4, IL-2, IL-17A and granzyme B was performed on a
Light Cycler (Roche Diagnostics, Mannheim, Germany)
using specific primers. The housekeeping gene fragment
of glyceraldehydes-3-phosphates dehydrogenase (GAPDH)
was used for verification of equal loading.
Western blotting
Cultured CD4
+ T lymphocytes were washed with ice-
cold PBS and lysed with a lysis buffer (1% Nonidet P 40,
50 mM Tris, pH 7.5, 100 mM NaCl, 50 mM NaF, 5
mM EDTA, 20 mM b-glycerophosphate, 1.0 mM
sodium orthovanadate, 10 μg/mL aprotinin and 10 μg/
mL leupeptin) for 20 minutes at 4°C. Insoluble material
was removed by centrifugation at 15,000 × g for 15 min
at 4°C. The supernatant was saved and the protein con-
centration was determined using the Bio-Rad protein
assay kit (Bio Rad, Hercules, CA). An identical amount
of protein (50 μg) for each lysate was subjected to 10%
SDS-polyacrylamide gel electrophoresis, and then trans-
ferred to a nitrocellulose membrane. Western blot ana-
lysis using phospho-specific STAT and anti-pan STAT
antibodies was performed with an ECL Western blotting
kit (Amersham, Little Chalfont, UK).
XTT cell proliferation assay
CD4
+ T cell proliferation was assessed by the 2, 3-bis-
[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxanilide (XTT) assay (Roche, Mannheim, Ger-
many). In briefly, CD4
+ T cells (10
4 cells/well) were pla-
ted into 96-well plates in the presence or absence of
various concentrations of CP690, 550. After stimulation
with a CD3 antibody for 48 hr, 50 μl of XTT labeling
mixture was added to each well. Finally, the optical den-
sity was measured at 490 nm with a reference wave
length at 690 nm in a microplate reader (Thermo Scien-
tific, Tokyo, Japan).
Apoptosis detection assay
Apoptosis and cell death were measured with a MEBCYTO
A p o p t o s i sK i t( M B L ,N a g o y a ) .I nb r i e f ,a f t e rs t i m u l a t i o n
with a CD3 antibody, cells were stained with 40 μg/ml pro-
pidium iodide (PI) and annexin V-FITC. The percentage of
annexin V-positive/PI-negative early apoptotic cells and PI-
positive dead cells were determined using an Epics XL flow
cytometer (Beckman Coulter).
Statistical analysis
Differences between groups were examined for statistical
significance using the Wilcoxon-Mann-Whitney U test.
P values less than 0.05 were considered statistically
significant.
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